An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2017
At a glance
- Drugs BI 754091 (Primary) ; BI 891065 (Primary)
- Indications Multiple myeloma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 30 Oct 2017 According to a Boehringer Ingelheim media release, the first patient has been enrolled in the study.
- 22 Sep 2017 Planned number of patients changed from 113 to 93.
- 22 Sep 2017 Status changed from not yet recruiting to recruiting.